Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for MASH and Obesity Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSD3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSD3 Recombinant Protein (Sec7 Domain / Full Length) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View PSD3 Products |
| Gene Delivery | PSD3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View PSD3 Products |
| Benchmark Ab | Anti-PSD3 Recombinant Antibody Sequence-verified positive control for Western Blot and IHC. |
View PSD3 Products |
| Validator | PSD3 siRNA Set Target-specific knockdown verification in hepatocyte models. |
View PSD3 Products |
| Related Target A | ARF6 Downstream GTPase effector of PSD3; critical for evaluating GEF activity. |
View ARF6 Products |
| Related Target B | PNPLA3 Key genetic driver in MASH; synergistic pathway target for metabolic disease. |
View PNPLA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility | High-titer Lentivirus for robust, stable expression in primary hepatocytes and HepG2 cells. |
| GEF Activity Assessment | Sequence-verified, high-purity recombinant PSD3 Sec7 domain proteins for cell-free nucleotide exchange assays. |
| Lack of Controls | Sequence-defined recombinant antibodies and validated siRNA sets included as assay benchmarks. |
| Off-Target Toxicity Screening | Homolog screening panels (PSD1, PSD2, PSD4) to ensure compound/siRNA specificity. |
Live PSD3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSD3 therapeutics is intensifying, with major players shifting focus from traditional target approaches to RNA interference (RNAi) and antisense oligonucleotides (ASOs) for metabolic diseases. As first-generation therapies for MASH (formerly NASH) and obesity reach the clinic, the next wave of R&D is targeting genetic modifiers like PSD3. Loss-of-function mutations in PSD3 have been clinically shown to protect against fatty liver disease and obesity, making intracellular inhibition via genetic medicine the dominant modality.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| siRNA / ASO | Alnylam Pharmaceuticals, Arrowhead | MASH, Steatohepatitis, Obesity | In vitro knockdown validation (Need sequence-verified siRNA and high-titer Lentivirus) |
| Small Molecule (GEF Inhibitor) | Academic/Biotech Consortia | Metabolic Syndrome, Hepatocellular Carcinoma | In vitro GEF exchange assays (Need high-purity recombinant PSD3 Sec7 domain) |
| CRISPR / Gene Editing | Emerging Gene Editing Biotechs | Severe Genetic Steatosis | Targeted cleavage and expression recovery assays (Need validated qPCR primers & antibodies) |